^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    M802

    i
    Other names: M802, M 802
    Associations

    News

    Trials
    Company:
    YZY Biopharma
    Drug class:
    CD3 agonist, HER2 antagonist
    Related drugs:
    Associations

    News

    Trials
    3years
    A Study of M802 (HER2 and CD3) in HER2-Positive Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=32, Not yet recruiting, Wuhan YZY Biopharma Co., Ltd. | Trial completion date: Mar 2021 --> Dec 2023 | Trial primary completion date: Dec 2020 --> Nov 2023
    Clinical • Trial completion date • Trial primary completion date
    |
    CEACAM5 (CEA Cell Adhesion Molecule 5) • MUC16 (Mucin 16, Cell Surface Associated) • CA 19-9 (Cancer antigen 19-9)
    |
    HER-2 positive • HER-2 expression • CEACAM5 expression • MUC16 expression
    |
    M802
    over4years
    A Study of M802 (HER2 and CD3) in HER2-Positive Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=32, Recruiting, Wuhan YZY Biopharma Co., Ltd.
    Clinical • New P1 trial
    |
    CEACAM5 (CEA Cell Adhesion Molecule 5) • MUC16 (Mucin 16, Cell Surface Associated) • CA 19-9 (Cancer antigen 19-9)
    |
    HER-2 positive • HER-2 expression • CEACAM5 expression • MUC16 expression
    |
    M802